2017 September

FDA Approves Neratinib for Extended Adjuvant Treatment of Breast Cancer

On July 17, 2017, the U.S. Food and Drug Administration approved neratinib (Nerlynx, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer to […]

Read More →